How to Administer Kayexalate (Sodium Polystyrene Sulfonate)
Kayexalate should be given orally at 15g (four level teaspoons) one to four times daily, suspended in 3-4 mL of water or syrup per gram of resin, with the patient sitting upright—but recognize that it is NOT appropriate for acute/emergency hyperkalemia and carries serious gastrointestinal risks including fatal bowel necrosis. 1
Critical Safety Warnings Before Administration
Do NOT use Kayexalate with sorbitol—the combination is associated with fatal intestinal necrosis 1. The FDA label explicitly warns against concomitant sorbitol administration due to severe gastrointestinal adverse events including bleeding, ischemic colitis, and perforation.
Absolute Contraindications
- Obstructive bowel disease
- Neonates with reduced gut motility
- Hypersensitivity to polystyrene sulfonate resins
- Patients who have not had a bowel movement post-surgery
- History of bowel obstruction, chronic constipation, inflammatory bowel disease, ischemic colitis, or previous bowel resection 1
Dosing and Preparation
Oral Administration (Preferred Route)
- Standard dose: 15g to 60g total daily, given as 15g doses (four level teaspoons) one to four times daily 1
- Preparation: Suspend each dose in a small quantity of water or syrup—approximately 3-4 mL of liquid per gram of resin
- Timing: Administer at least 3 hours before or after other oral medications (6 hours in gastroparesis) 1
- Position: Patient must be in upright position during administration 1
- Storage: Prepare suspension fresh and use within 24 hours; do NOT heat as this alters exchange properties 1
- Measurement: One level teaspoon = approximately 3.5g of sodium polystyrene sulfonate and 15 mEq of sodium 1
Rectal Administration (Retention Enema)
- Dose: 30g to 50g every 6 hours 1
- Technique:
- Perform initial cleansing enema first
- Insert soft, large (French 28) rubber tube 20 cm into rectum with tip in sigmoid colon and tape in place
- Administer as warm (body temperature) emulsion in 100 mL aqueous vehicle
- Flush with 50-100 mL fluid
- Use somewhat thicker suspension but do NOT form a paste
- Agitate emulsion gently during administration
- Retain as long as possible
- Follow with cleansing enema using non-sodium containing solution (up to 2 liters) 1
Clinical Context and Limitations
Kayexalate is NOT for acute/emergency hyperkalemia due to delayed onset of action 1. Current guidelines from the European Society of Cardiology explicitly recommend against chronic use of sodium polystyrene sulfonate due to lack of rigorous placebo-controlled trials proving efficacy and safety, plus severe gastrointestinal side effects 2. The 2025 European Heart Journal guidelines do not recommend SPS as a preferred option for recurrent hyperkalemia management 3.
Evidence of Efficacy
When used chronically (not acutely), Kayexalate shows modest potassium-lowering effects:
- Reduces serum potassium by approximately 0.93-1.04 mEq/L over several days 4, 5
- One randomized trial showed mean reduction of 1.04 mEq/L over 7 days in mild hyperkalemia (5.0-5.9 mEq/L) 4
- Long-term use (median 15 months) reduced potassium from 5.9 to 4.8 mmol/L in CKD patients 6
Monitoring Requirements
- Serum potassium: Monitor closely for severe hypokalemia (can occur) 1
- Serum sodium: Expect slight elevation due to sodium exchange 6
- Magnesium and calcium: Monitor as small amounts can be lost during treatment 1
- Bowel function: Discontinue immediately if constipation develops 1
Preferred Alternatives
Current guidelines strongly favor newer potassium binders over Kayexalate:
- Sodium zirconium cyclosilicate (SZC) and patiromer are recommended as first-line agents for chronic/recurrent hyperkalemia 3, 2
- These newer agents have demonstrated superior efficacy in maintaining normokalemia for at least one year and are considered cost-effective 3
- They lack the serious gastrointestinal safety concerns associated with SPS 2, 7, 8
When Kayexalate Might Still Be Used
Only consider in patients with:
- Normal bowel function
- No contraindications listed above
- Mild chronic hyperkalemia (not acute)
- Limited access to newer potassium binders
- Ability to tolerate gastrointestinal side effects (constipation is common) 6
The 2018 ESC consensus explicitly states that chronic use of SPS should be avoided and that newer potassium binders with different counter-exchange ions should be preferred alternatives 2.